mTOR Pathway Expression as Potential Predictive Biomarker in Patients with Advanced Neuroendocrine Tumors Treated with Everolimus.
14 Luglio 2021
|By TPM
Gelsomino F, Casadei-Gardini A, Caputo F, Rossi G, Bertolini F, Petrachi T, Spallanzani A, Pettorelli E, Kaleci S, Luppi G.